GT Biopharma Inc

Change company Symbol lookup

Select an option...

GTBP GT Biopharma Inc

UNH UnitedHealth Group Inc

BAC Bank of America Corp

WSO Watsco Inc

LITB LightInTheBox Holding Co Ltd

CVCY Central Valley Community Bancorp

AFAQU AF Acquisition Corp

HCIIW Hudson Executive Investment Equity II Warrant Exp 31 Jan 2027 *W EXP 01/31/2027

MEDS TRxADE Health Inc

HCICW Hennessy Capital Investment V Equity Warrant Exp 15 Jan 2025 *W EXP 01/15/2025

Go

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The Company's TriKE platform generate therapeutics designed to harness and enhance the cancer killing abilities of a patient's own natural killer (NK) cells. GTB-3550 is the Company's TriKE product candidate, which is a single-chain, tri-specific recombinant fusion protein construct consisting of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The Company is focused on studying this anti-CD16-IL-15-anti-CD33 TriKE in CD33 positive leukemias, a marker expressed on tumor cells in acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS).